IL233481A0 - Peptides and methods of using them - Google Patents

Peptides and methods of using them

Info

Publication number
IL233481A0
IL233481A0 IL233481A IL23348114A IL233481A0 IL 233481 A0 IL233481 A0 IL 233481A0 IL 233481 A IL233481 A IL 233481A IL 23348114 A IL23348114 A IL 23348114A IL 233481 A0 IL233481 A0 IL 233481A0
Authority
IL
Israel
Prior art keywords
peptides
methods
same
Prior art date
Application number
IL233481A
Other languages
English (en)
Hebrew (he)
Original Assignee
Serpin Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serpin Pharma Llc filed Critical Serpin Pharma Llc
Publication of IL233481A0 publication Critical patent/IL233481A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL233481A 2012-01-09 2014-07-02 Peptides and methods of using them IL233481A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261584517P 2012-01-09 2012-01-09
US201261699571P 2012-09-11 2012-09-11
PCT/US2013/020498 WO2013106273A2 (en) 2012-01-09 2013-01-07 Peptides and methods of using same

Publications (1)

Publication Number Publication Date
IL233481A0 true IL233481A0 (en) 2014-08-31

Family

ID=47595077

Family Applications (1)

Application Number Title Priority Date Filing Date
IL233481A IL233481A0 (en) 2012-01-09 2014-07-02 Peptides and methods of using them

Country Status (10)

Country Link
US (6) US9951104B2 (OSRAM)
EP (2) EP3381461B1 (OSRAM)
JP (1) JP6416627B2 (OSRAM)
AU (3) AU2013208293B2 (OSRAM)
CA (2) CA3077804C (OSRAM)
DK (2) DK3381461T3 (OSRAM)
ES (2) ES2676028T3 (OSRAM)
IL (1) IL233481A0 (OSRAM)
MX (1) MX365403B (OSRAM)
WO (1) WO2013106273A2 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3077804C (en) 2012-01-09 2023-07-25 Serpin Pharma, Llc Peptides and methods of using same
WO2014197524A2 (en) * 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
EP3019188B1 (en) 2013-07-08 2022-03-09 The University of Utah Research Foundation A peptide and the use thereof in the treatment of inflammatory disorders
EP3193903A4 (en) * 2014-09-16 2018-03-14 Bioincept LLC Compositions and methods for treating acute radiation syndrome
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US20160256611A1 (en) * 2015-03-04 2016-09-08 Microvention, Inc. Drug Delivery Device
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11020462B2 (en) * 2015-08-28 2021-06-01 Serpin Pharma Methods for treatment of diseases
CN108602787A (zh) 2015-11-09 2018-09-28 库特克希米公司 精氨酸牙龈卟啉菌蛋白酶的抑制剂
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN112020555B (zh) * 2018-05-02 2024-06-21 国立大学法人新潟大学 肽及其应用
EP4003391A4 (en) 2020-07-06 2023-02-22 Serpin Pharma, LLC PEPTIDES AND THEIR METHODS OF USE

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
FI81498C (fi) 1987-01-13 1990-11-12 Biocon Oy Kirurgiska material och instrument.
US5580561A (en) * 1987-03-06 1996-12-03 Cercek; Boris Methods and pharmaceutical compositions for blocking suppression of immune defense mechanisms using an antibody, a factor, or an antisense peptide
US5270171A (en) * 1987-03-06 1993-12-14 Boris Cercek Cancer-associated SCM-recognition factor, preparation and method of use
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5353535A (en) 1990-11-05 1994-10-11 Plumly George W Floor type advertising apparatus
JP4116072B2 (ja) 1992-08-27 2008-07-09 バイオクローンズ（プロプライエタリー）リミテッド 逆向き、鏡像体および逆向き鏡像体合成ペプチド類似物
US5618563A (en) 1992-09-10 1997-04-08 Children's Medical Center Corporation Biodegradable polymer matrices for sustained delivery of local anesthetic agents
CA2145641C (en) 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
US5514653A (en) * 1994-09-09 1996-05-07 Washington University Method of blocking the SEC receptor
US5665557A (en) 1994-11-14 1997-09-09 Systemix, Inc. Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof
WO1997014809A2 (en) 1995-10-16 1997-04-24 Dana-Farber Cancer Institute Novel expression vectors and methods of use
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
EP1071806B1 (en) 1998-04-24 2004-06-16 University of Florida Recombinant adeno-associated viral vector encoding alpha-1-antitrypsin for gene therapy
US20100210528A1 (en) * 1999-03-05 2010-08-19 Leland Shapiro Compositions, methods and uses for inhibition and/or treatment of influenza infection
AU2003221745A1 (en) 2002-04-19 2003-11-03 University Of Florida rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES
PL2520654T3 (pl) 2003-08-26 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych
WO2005070445A2 (en) 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
EP2302393A1 (en) 2004-05-21 2011-03-30 The Institute for Systems Biology Compositions and methods for quantification of serum glycoproteins
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
EP1973547A1 (en) 2005-12-23 2008-10-01 Vital Health Sciences Pty Ltd. Compounds having cytokine modulating properties
EP1996215A2 (en) 2006-02-28 2008-12-03 Trustees Of Boston University Metabolic regulators and uses thereof
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
US20090203602A1 (en) * 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
US20100267052A1 (en) 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
US8623830B2 (en) 2006-09-12 2014-01-07 Beth Israel Deaconess Medical Center, Inc. Compositions containing α-1-antitrypsin and methods for use
ES2534434T3 (es) 2007-08-30 2015-04-22 Curedm Group Holdings, Llc Composiciones y métodos de uso de péptidos proislotes y análogos de los mismos
WO2009046015A2 (en) 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US7923253B2 (en) * 2007-11-05 2011-04-12 Battelle Memorial Institute Method for identifying type I diabetes mellitus in humans
WO2011109768A2 (en) 2010-03-04 2011-09-09 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating cardiac conditions
WO2011126882A2 (en) * 2010-03-30 2011-10-13 American Type Culture Collection Therapeutic peptides and their derivatives and therapeutic uses thereof
US9005615B2 (en) 2010-05-06 2015-04-14 The Feinstein Institute For Medical Research Methods for treatment of inflammatory diseases
CA3077804C (en) 2012-01-09 2023-07-25 Serpin Pharma, Llc Peptides and methods of using same
CA2896951A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
WO2014197524A2 (en) 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
KR20160146242A (ko) 2015-06-12 2016-12-21 현대자동차주식회사 터보차저 엔진의 재순환 밸브 구동 장치 및 방법
US11020462B2 (en) 2015-08-28 2021-06-01 Serpin Pharma Methods for treatment of diseases

Also Published As

Publication number Publication date
US10899797B2 (en) 2021-01-26
ES2676028T3 (es) 2018-07-16
CA3077804C (en) 2023-07-25
AU2017258892B2 (en) 2019-11-14
DK2802338T3 (en) 2018-06-14
AU2013208293A1 (en) 2014-06-26
WO2013106273A3 (en) 2013-12-19
US8975224B2 (en) 2015-03-10
US20140378372A1 (en) 2014-12-25
MX365403B (es) 2019-05-31
WO2013106273A2 (en) 2013-07-18
JP2015504073A (ja) 2015-02-05
AU2019253814B2 (en) 2022-03-10
AU2013208293B2 (en) 2017-08-10
ES2871544T3 (es) 2021-10-29
JP6416627B2 (ja) 2018-10-31
CA2859777A1 (en) 2013-07-18
AU2013208293A2 (en) 2016-01-28
US20170029465A9 (en) 2017-02-02
US9951104B2 (en) 2018-04-24
CA3077804A1 (en) 2013-07-18
US20200017550A1 (en) 2020-01-16
CA2859777C (en) 2020-06-30
US20150133375A1 (en) 2015-05-14
US20250346632A1 (en) 2025-11-13
EP2802338A2 (en) 2014-11-19
AU2019253814A1 (en) 2019-11-14
BR112014016734A2 (pt) 2020-10-27
US10214562B2 (en) 2019-02-26
EP3381461B1 (en) 2021-03-10
US12291581B2 (en) 2025-05-06
AU2017258892A1 (en) 2017-11-30
US20130274187A1 (en) 2013-10-17
HK1203161A1 (en) 2015-10-23
MX2014007799A (es) 2014-10-24
DK3381461T3 (da) 2021-05-17
US20210188912A1 (en) 2021-06-24
EP2802338B1 (en) 2018-03-07
EP3381461A1 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
ZA201404962B (en) Modified mini-hepcidin peptides and methods of using thereof
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
EP2928562A4 (en) PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE
SG11201504049VA (en) Compounds and their methods of use
IL233481A0 (en) Peptides and methods of using them
ZA201405858B (en) Recombinant microorganisms and methods of use thereof
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
GB201201100D0 (en) Polypeptides and methods
SG11201500111VA (en) Peptides and uses thereof
EP2819686A4 (en) PROTHYMOSIN ALPHA VARIANTS AND METHODS OF USE
GB201217027D0 (en) Near live-migration of operating system and application
SG10201701828WA (en) Peptides and their uses
EP2914293A4 (en) METHOD OF USE OF FVIII POLYPEPTIDE
IL237135B (en) Peptide library and their uses
EP2825548A4 (en) MODIFIED KISSPEPTIN PEPTIDES AND USES THEREOF
IL239043A0 (en) Thrombin solution and methods of using it
EP2836227A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
GB201416065D0 (en) Catalysts and methods of making and using catalysts
IL277033A (en) Thrombin solution and methods of using it
GB201214769D0 (en) Methodsa and peptides
GB201210303D0 (en) Polypeptides and methods
GB201210911D0 (en) Clamping means and method of use thereof
GB201301640D0 (en) Methods and peptides

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed